Kintor Pharmaceutical (HKSE:09939) EBIT per Share : HK$-2.70 (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Kintor Pharmaceutical EBIT per Share?

Kintor Pharmaceutical's EBIT per Share for the six months ended in Dec. 2023 was HK$-2.17. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-2.70.

During the past 3 years, the average EBIT per Share Growth Rate was -21.10% per year. During the past 5 years, the average EBIT per Share Growth Rate was -55.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Kintor Pharmaceutical's EBIT per Share or its related term are showing as below:

HKSE:09939' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -104.2 Med: -60.6 Max: -21.1
Current: -21.1

During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Kintor Pharmaceutical was -21.10% per year. The lowest was -104.20% per year. And the median was -60.60% per year.

HKSE:09939's 3-Year EBIT Growth Rate is ranked worse than
75.08% of 1300 companies
in the Biotechnology industry
Industry Median: 3.4 vs HKSE:09939: -21.10

Kintor Pharmaceutical's EBIT for the six months ended in Dec. 2023 was HK$-932.56 Mil.

Kintor Pharmaceutical EBIT per Share Historical Data

The historical data trend for Kintor Pharmaceutical's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintor Pharmaceutical EBIT per Share Chart

Kintor Pharmaceutical Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.70

-1.94

-2.89

-2.80

-2.70

Kintor Pharmaceutical Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT per Share	Get a 7-Day Free Trial						-1.73	-1.65	-1.24	-0.53	-2.17

Kintor Pharmaceutical EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Kintor Pharmaceutical's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1158.499	/	429.069
=	-2.70

Kintor Pharmaceutical's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-932.559	/	429.686
=	-2.17

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-2.70

Kintor Pharmaceutical (HKSE:09939) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Kintor Pharmaceutical EBIT per Share Related Terms

Thank you for viewing the detailed overview of Kintor Pharmaceutical's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Kintor Pharmaceutical (HKSE:09939) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintor Pharmaceutical Ltd (HKSE:09939) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

KNTPF:USA

Address

No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.kintor.com.cn

Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-ß (GT90008), and AR-PROTAC Compound (GT20029). It operates in a single segment focusing on the research and development of medical products.

Executives

Tong Youzhi	2101 Beneficial owner
Kt International Investment Limited	2101 Beneficial owner
Guo Chuangxing	2201 Interest of corporation controlled by you
Kg Development Limited	2101 Beneficial owner
Nomura Holdings, Inc.	2201 Interest of corporation controlled by you
Tong Youzhi	2201 Interest of corporation controlled by you
Zhu Hai Ge Li Jin Rong Tou Zi Guan Li You Xian Gong Si	2101 Beneficial owner
Zhu Hai Ge Li Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Sovereign Fiduciaries (hong Kong) Limited
Kiya Company Limited
Lian Xiang Kong Gu Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Nan Ming You Xian Gong Si	2201 Interest of corporation controlled by you
Shi Xian You Xian Gong Si	2101 Beneficial owner

Kintor Pharmaceutical (HKSE:09939) Headlines

No Headlines